The Patent Finder
ER

Eisai R&D Management Co., Ltd.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

234 patents currently held

38 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
11 more records may belong here and await a decision; they are not counted.

The next term ends in Nov 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
43
Ending by 2030
Nov 2026
Next term end
159
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
EZH2 Inhibitors for Treating Lymphoma US 11,642,347
Cited by 11 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2036.
Ends Apr 2036 · High confidence
Also notable
Intermediates and Methods for the Synthesis of Halichondrin B Analogs US 8,987,479
Cited by 59 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Ends Dec 2029 · Medium confidence
Also notable
Compounds Useful in the Synthesis of Halichondrin B Analogs US 8,927,597
Cited by 56 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Ends Mar 2031 · Medium confidence

Formerly held, still cited

Notable
Cited by 51 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
now held by Epizyme, Inc.
Ends Apr 2032 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Nov 26 to 30, 2026 · next Nov 26
  • 4 fees due Dec 4 to 20, 2026 · next Dec 4
  • 3 fees due Jan 4 to 25, 2027 · next Jan 4
  • 1 fee due Feb 15, 2027
    The maintenance fee for Macrocyclic Compound and Uses Thereof (US 11,725,015) comes due Feb 15, 2027. Unpaid by Aug 16, 2027, it lapses early.
  • 7 fees due Mar 8 to 22, 2027 · next Mar 8
  • 3 fees due Apr 1 to 29, 2027 · next Apr 1
  • 2 fees due May 3 to 14, 2027 · next May 3
  • 6 fees due Jun 3 to 24, 2027 · next Jun 3
  • 3 fees due Jul 5 to 21, 2027 · next Jul 5
  • 2 fees due Aug 4 to 18, 2027 · next Aug 4
  • 1 fee due Sep 12, 2027
    The maintenance fee for Certain Pladienolide Compounds and Methods of Use (US 11,926,619) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
  • 5 fees due Oct 2 to 14, 2027 · next Oct 2
  • 3 fees due Nov 5 to 10, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,504,746Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
In force
 · High confidence
In forceHigh confidence
US 7,532,136Analog to Digital Converter Unit
In force
 · High confidence
In forceHigh confidence
US RE46,965Intermediates for the Preparation of Analogs of Halichondrin B
In force
 · Low confidence
In forceLow confidence
US 8,481,565Method for Stabilizing Anti-Dementia Drug
In force
 · Medium confidence
In forceMedium confidence
US 7,550,483Amorphous Salt of 4-(3-Chiloro-4-(CYCLOPROPLYLAMINOCARBONYL)AMINOPHENOXY)-7-Method-6-Quinolinecarboxamide and Process for Preparing the Same
In force
 · High confidence
In forceHigh confidence
US 9,006,256Antitumor Agent for Thyroid Cancer
In force
 · Medium confidence
In forceMedium confidence
US 9,931,295Stabilized Pharmaceutical Composition
In force
 · High confidence
In forceHigh confidence
US 7,691,882Heterocycles Substituted Pyridine Derivatives and Antifungal Agent Containing Thereof
In force
 · High confidence
In forceHigh confidence
US 8,058,444Heterocycle-Substituted Pyridine Derivative's Salt or Crystal Thereof
In force
 · High confidence
In forceHigh confidence
US 8,137,926Kit for Assaying EPHA4 Processing by Gamma-Secretase
In force
 · High confidence
In forceHigh confidence
10 of 234 patents shown.
Pro members see all 234.
Pro members: see all 234 patents
Also on record, not counted in the 234: 38 patents in force now held by others · 354 patents ended · 87 applications pending · 335 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited